Yazar "Albayrak M." seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Comparison of Hashin and Puck criterions for failure behavior of pin loaded composite plates
    (John Wiley and Sons Inc, 2024) Dogan C.; Kaman M.O.; Erdem S.; Albayrak M.
    In this study, the failure behavior of carbon fiber-reinforced pin-jointed composite plates were analyzed for different criteria. For this purpose, composite plates with a single and double pin joints were prepared from four layers carbon fiber composites. The effect of pin number, pin position on plate damage load and type was investigated experimentally and numerically under the tensile test. Numerically, progressive damage analysis was performed using Hashin and Puck failure criteria, and the approach rates to the experimental results were determined. It was observed that the experimental results obtained for single pin joint composites and the numerical data obtained using the Puck damage criterion were at least 87 % compatible, and this rate was determined as 85 % for the Hashin failure criterion. For the double pin jointed composites, it was seen that the experimental results and the results of the Puck damage criterion were compatible with at least 90 %, and this rate was obtained as 84 % for the Hashin failure criterion. The dominant damage type seen in the specimen is matrix shear and fiber compression according to the Hashin damage criterion, inter fiber failure in transverse tension for Puck. © 2024 Wiley-VCH GmbH.
  • Küçük Resim Yok
    Öğe
    Pralatrexate experience in peripheral T-cell lymphoma: A multicenter retrospective study from Turkey
    (Zerbinis Publications, 2021) Dal M.S.; Merdin A.; Erkurt M.A.; Ekinci Ö.; Albayrak M.; Hacıoglu S.K.; Kaya A.
    Purpose: Pralatrexate is a new generation antifolate treatment agent used for the treatment of relapsed or refractory peripheral T-cell lymphomas. This study aims to determine the general characteristics of the patients receiving pralatrexate therapy in Turkey, contributing to the literature on the effectiveness of pralatrexate therapy in peripheral T-cell lymphomas by determining the response levels of such patients to the therapy. The study also attempts to clinically examine the major side effects observed in patients during treatment with pralatrexate. Methods: The study included patients with peripheral T-cell lymphoma followed up in the hematology units of several hospitals in Turkey. Overall, 20 patients aged 18 and over were included in the study. Results: The median age at the time of diagnosis was 58.5 years. PTCL-NOS (Peripheral T-cell lymphoma, not otherwise specified) subtype was in 40% of patients, making the PTCL-NOS the most common subtype in the study. In general, most patients were diagnosed with disease at an advanced stage. Pralatrexate therapy was given to the patients at a median treatment line of 3.5. Pralatrexate dose reduction was required in only 3 patients (15%). Response to pralatrexate therapy with partial remission (PR) and above was observed in 11 (55%) of the patients. Conclusion: Pralatrexate seemed to be a promising novel treatment in relapsed refractory PTCL patients. However, patients receiving pralatrexate should be followed up carefully for skin reactions, mucosal side effects, thrombocytopenia and neutropenia. © 2021 Zerbinis Publications. All rights reserved.